title: [Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience].
abstract: Rivaroxaban is direct oral factor Xa inhibitor indicated for tromboembolic event rate reduction in patients with non-valvular atrial fibrillation. Knowledge of rivaroxaban efficacy and safety comes from a phase III randomized clinical trial ROCKET AF. In the present, we have more evidence of rivaroxaban efficacy from real-life clinical studies. XANTUS study was first international prospective observational real-life study documenting use of rivaroxaban in stroke prevention in a broad population of patients with non-valvular atrial fibrillation. The incidence of major bleed-ing and tromboembolic events was in real clinical practice low. RELIEF study was a second important study describing use of rivaroxaban in real-life clinical practice. The aim of this rectrospective study was to compare effectiveness of newly indicated rivaroxaban treatment with the vitamin K antagonists treatment. Our experience shows low incidence of bleeding with this therapy too.Key words: anticoagulation therapy - non-valvular atrial fibrillation - real-life studies - rivaroxaban.
authors.forename: Filip
authors.initials: F
authors.lastname: Málek
mesh_terms: D000284:Administration, Oral; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban / Q000627:therapeutic use*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
chemical_list: D065427:Factor Xa Inhibitors; D000069552:Rivaroxaban